Drugs / Pneumococcal conjugate vaccine (PCV13)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04745559 | Feb 2021 → Jul 2025 overdue | follicular lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pneumococcal conjugate vaccine (PCV13) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04745559 ↗ |
| Modality | Vaccine | “Licensed heptavalent pneumococcal conjugate vaccine (PCV13, Pneumococcal 13-valent conjugate vaccine” NCT04745559 ↗ |
| Route | Intramuscular | “will be administered intramuscularly three times” NCT04745559 ↗ |